The Future of Chronic Pancreatitis Therapies

Meet two leaders at the forefront of new developments

February 23, 2022 2:00 PM

Join us in conversation with industry leaders who are developing therapies for chronic pancreatitis and diabetes.

Mission: Cure encourages impact investors to fund pancreatitis therapies that would not otherwise make it out of the lab. Mission Cure Capital, a separate impact investment company, invests in high impact, commercially-promising treatments for pancreatitis and its symptoms.

Join us to learn about this approach and learn from industry leaders who are developing therapies for chronic pancreatitis and diabetes.

With John Mellnik, PhD, CEO, Path BioAnalytics, and Tony Kolton, CEO, Regenerative Medical Solutions

To register, click here.